title: [Clinical significance of survivin expression in peripheral T-cell lymphoma].
abstract: OBJECTIVE
  Peripheral T-cell lymphoma (PTCL) accounts for about 10%-15% of non-hodgkin's lymphomas (NHL), usually associated with short clinical course and poor prognosis. The over expression of survivin, a member of inhibitor of apoptotic protein (IAP), is regarded as a poor prognostic index in many malignant tumors. This study was to detect the expression of survivin in PTCL, and analyze its correlation to clinical features and prognosis of PTCL.
  
  
  METHODS
  The expression of survivin in 51 specimens of naive PTCL was detected by immunohistochemistry. The correlations of survivin expression to clinical features and prognosis were analyzed by SPSS10.0 software.
  
  
  RESULTS
  The positive rate of survivin was 82.3%. Its expression had no significant correlations to sex, age, clinical stage, the number of extranodal lesions, performance status, serum level of lactate dehydrogenase, B symptoms, and international prognostic index (P>0.05). The 5-year overall survival rate of the 51 patients was 32.67%. The patients with positive survivin expression had poorer 5-year overall survival than negative patients (25.0% vs. 75.0%, P=0.03). Cox regression model showed that survivin was an independent poor prognostic index of PTCL.
  
  
  CONCLUSIONS
  Survivin is a useful prognostic index of PTCL. We can screen out the cases which may have poor prognosis early by combining survivin expression with IPI, and improve the treatment outcome of PTCL.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China. xxjwen@163.com
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Xiang
authors.forename: You-Jian
authors.initials: YJ
authors.lastname: He
authors.forename: Yu-Hong
authors.initials: YH
authors.lastname: Li
authors.forename: He
authors.initials: H
authors.lastname: Huang
authors.forename: Fei
authors.initials: F
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D012074:Remission Induction; D015996:Survival Rate; D000077022:Survivin; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D000077022:Survivin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone